The Leukemia & Lymphoma Society of Canada (LLSC) invites proposals from Canadian researchers for its Operating Grant Program, a two-year funding opportunity supporting innovative projects that advance the understanding, diagnosis, or treatment of blood cancers. The program aims to fuel transformative research that can lead to significant clinical or scientific breakthroughs.
Eligibility Criteria:
-
Open to Canadian blood cancer researchers affiliated with recognized academic or research institutions.
-
Projects must focus on leukemia, lymphoma, myeloma, or related hematologic malignancies.
-
Applicants must demonstrate the project’s scientific merit, feasibility, and potential impact on patient outcomes.
-
Collaborative and multicentre projects are encouraged, particularly those addressing novel therapeutic or diagnostic strategies.
Funding Details:
-
Funding amount: Up to CAD 100,000 per year for two years (maximum total: CAD 200,000).
-
Funding start date: Fall 2026.
- Partnered funding opportunities include:
-
Cancer Research Society (CRS): Co-funding five Operating Grants on all cancer types.
-
Cell Therapy Transplant Canada (CTTC): Co-funding one multicentre project focused on improving the outcomes, efficacy, and safety of HCT/CT in Canada.
-
Myeloma Canada: Co-funding one Operating Grant focused on myeloma research, particularly accelerating Canadian academic immunotherapy development.
-
Deadline:
-
Letter of Intent (LOI) deadline: December 4, 2025 (4:00 p.m. ET).
-
Notification of full application invitation: December 2025.
-
Full Application deadline: February 4, 2026 (4:00 p.m. ET).
-
Review Panel Meeting: April 2026.
-
Notification of Awards: Summer 2026.
-
Award Start Date: Fall 2026.
Where to Go For Further Information: